Recent Announcements
Recruitment for Non-Invasive Parkinson’s Phase3/Pivotal Study Slated for December
The maker of the widely anticipated Celeste® specialized phototherapy device, PhotoPharmics, today announced plans to begin recruitment for the Celeste Light for PD trial in December.
“Multiple forces have aligned to make the timing for our pivotal clinical study here and now,” said Kent Savage, PhotoPharmics CEO. “We have leveraged this time to work with FDA, gather input from our clinical advisory board, and coordinate with the trial team at the University of Rochester Medical Center. Once we finalize related funding details, recruitment will begin in earnest.”
Savage added, “Fortunately, demand for non-pharmaceutical and non-invasive solutions like Celeste from people with Parkinson’s and their care partners has only increased. We have heard from thousands of people patiently waiting for the opportunity to experience the benefits of Celeste.”
Featured Article
How Parkinson’s Affects Sleep and Vice-Versa
When most people think of Parkinson’s Disease (PD), the first symptom to come to mind are physical tremors and other movement symptoms. However, most people with Parkinson’s experience a wide range of non-motor symptoms that can often be more disruptive to their daily...
How Parkinson’s Affects Sleep and Vice-Versa
When most people think of Parkinson’s Disease (PD), the first symptom to come to mind are physical tremors and other movement symptoms. However, most people with Parkinson’s experience a wide range of non-motor symptoms that can often be more disruptive to their daily...
Problem displaying Facebook posts. Backup cache in use.
Click to show error
Archived Content